Keytruda takes on childhood liver cancer: new hope for relapsed patients?
Disease control
Recruiting now
This phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in children and young adults up to age 30 with relapsed or hard-to-treat liver cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Researchers will also study how the i…
Phase: PHASE2 • Sponsor: Allison O'Neill, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC